Summary of Significant Accounting Policies (Tables)
|
9 Months Ended |
Sep. 30, 2022 |
|---|
| Accounting Policies [Abstract] |
|
| Summary of Components of Marketable Securities |
The
following is a summary of the components of our marketable debt securities and the underlying fair value input level tier hierarchy (in
thousands) (see fair value of financial instruments):
Summary of Components of Marketable Securities
| |
|
As of September 30, 2022 |
|
| |
|
Amortized |
|
|
Unrealized |
|
|
Unrealized |
|
|
Fair |
|
| |
|
Cost |
|
|
Gains |
|
|
Losses |
|
|
Value |
|
| U.S. government obligations |
|
$ |
1,448 |
|
|
$ |
- |
|
|
$ |
(93 |
) |
|
$ |
1,355 |
|
| Corporate obligations |
|
|
2,342 |
|
|
|
129 |
|
|
|
(148 |
) |
|
|
2,323 |
|
| |
|
$ |
3,790 |
|
|
$ |
129 |
|
|
$ |
(241 |
) |
|
$ |
3,678 |
|
| |
|
As of December 31, 2021 |
|
| |
|
Amortized |
|
|
Unrealized |
|
|
Unrealized |
|
|
Fair |
|
| |
|
Cost |
|
|
Gains |
|
|
Losses |
|
|
Value |
|
| U.S. government obligations |
|
$ |
650 |
|
|
$ |
17 |
|
|
$ |
- |
|
|
$ |
667 |
|
| Corporate obligations |
|
|
8,304 |
|
|
|
- |
|
|
|
(192 |
) |
|
|
8,112 |
|
| |
|
$ |
8,954 |
|
|
$ |
17 |
|
|
$ |
(192 |
) |
|
$ |
8,779 |
|
|
| Schedule of Accounts Receivable Net |
Accounts
are written off as uncollectible at the time we determine that collections are unlikely. Accounts receivable, net is comprised of the
following (in thousands):
Schedule of Accounts Receivable Net
| |
|
September 30, 2022 |
|
|
December 31, 2021 |
|
| Trade accounts receivable |
|
$ |
38,231 |
|
|
$ |
18,520 |
|
| Unbilled accounts receivable |
|
|
6,031 |
|
|
|
23,089 |
|
| Accounts receivable, gross |
|
|
44,262 |
|
|
|
41,609 |
|
| Less allowances |
|
|
(6,430 |
) |
|
|
(3,901 |
) |
| Total accounts receivable |
|
$ |
37,832 |
|
|
$ |
37,708 |
|
|
| Schedule of Components of Inventory |
At
September 30, 2022 and December 31, 2021, the components of inventory are as follows (in thousands):
Schedule of Components of Inventory
| |
|
September 30, 2022 |
|
|
December 31, 2021 |
|
| Diagnostic services testing material |
|
$ |
2,271 |
|
|
$ |
2,989 |
|
| Raw materials |
|
|
1,904 |
|
|
|
1,514 |
|
| Work in process |
|
|
609 |
|
|
|
260 |
|
| Finished goods |
|
|
383 |
|
|
|
272 |
|
| Inventory |
|
$ |
5,167 |
|
|
$ |
5,035 |
|
| Inventory valuation reserve |
|
|
(255 |
) |
|
|
(435 |
) |
| Inventory, net |
|
$ |
4,912 |
|
|
$ |
4,600 |
|
|
| Schedule of Fair Value of Financial Instruments |
Schedule of Fair Value of Financial Instruments
| |
|
As of September 30, 2022 |
|
| |
|
Level 1 |
|
|
Level 2 |
|
|
Level 3 |
|
|
Total |
|
| U.S. government obligations |
|
$ |
- |
|
|
$ |
1,355 |
|
|
$ |
- |
|
|
$ |
1,355 |
|
| Corporate obligations |
|
|
- |
|
|
|
2,323 |
|
|
|
- |
|
|
|
2,323 |
|
| |
|
$ |
- |
|
|
$ |
3,678 |
|
|
$ |
- |
|
|
$ |
3,678 |
|
| |
|
As of December 31, 2021 |
|
| |
|
Level 1 |
|
|
Level 2 |
|
|
Level 3 |
|
|
Total |
|
| U.S. government obligations |
|
$ |
- |
|
|
$ |
667 |
|
|
$ |
- |
|
|
$ |
667 |
|
| Corporate obligations |
|
|
- |
|
|
|
8,112 |
|
|
|
- |
|
|
|
8,112 |
|
| Marketable equity securities |
|
|
76 |
|
|
|
- |
|
|
|
- |
|
|
|
76 |
|
| |
|
$ |
76 |
|
|
$ |
8,779 |
|
|
$ |
- |
|
|
$ |
8,855 |
|
|
| Schedule of Deferred Revenue |
The
following table disaggregates our deferred revenue by recognition period (in thousands):
Schedule of Deferred Revenue
| Recognition Period |
|
September 30, 2022 |
|
|
December 31, 2021 |
|
| 0-12 Months |
|
$ |
2,958 |
|
|
$ |
2,034 |
|
| 13-24 Months |
|
|
626 |
|
|
|
530 |
|
| Over 24 Months |
|
|
301 |
|
|
|
375 |
|
| Total |
|
$ |
3,885 |
|
|
$ |
2,939 |
|
|
| Schedule of Disaggregation by Revenue |
The
following table disaggregates the Company’s revenue by revenue source for the three and nine months ended September 30, 2022 and
2021 (in thousands):
Schedule of Disaggregation by Revenue
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
For the three months ended |
|
|
For the nine months ended |
|
| Revenue by Customer Type |
|
September 30, 2022 |
|
|
September 30, 2021 |
|
|
September 30, 2022 |
|
|
September 30, 2021 |
|
| Diagnostic services |
|
$ |
20,542 |
|
|
$ |
7,142 |
|
|
$ |
91,613 |
|
|
$ |
27,416 |
|
| Contract manufacturing |
|
|
2,749 |
|
|
|
1,120 |
|
|
|
5,662 |
|
|
|
4,069 |
|
| Retail and others |
|
|
357 |
|
|
|
1,210 |
|
|
|
1,369 |
|
|
|
2,400 |
|
| Genomic products and services |
|
|
552 |
|
|
|
- |
|
|
|
2,180 |
|
|
|
- |
|
| Total revenue, net |
|
$ |
24,200 |
|
|
$ |
9,472 |
|
|
$ |
100,824 |
|
|
$ |
33,885 |
|
|